For the quarter ending 2026-03-31, RXRX made $6,472K in revenue. -$117,504K in net income. Net profit margin of -1815.57%.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Total revenue | 6,472 | 35,538 | 5,175 | 19,223 |
| Cost of revenue | 12,490 | 14,276 | 14,687 | 20,161 |
| Research and development | 87,896 | 95,939 | 121,062 | 128,636 |
| General and administrative | 34,591 | 33,658 | 41,628 | 46,653 |
| Total operating costs and expenses | 134,977 | 143,873 | 177,377 | 195,450 |
| Loss from operations | -128,505 | -108,335 | -172,202 | -176,227 |
| Other income (loss), net | 6,397 | 232 | 9,952 | 4,330 |
| Loss before income tax benefit | -122,108 | -108,103 | -162,250 | -171,897 |
| Income tax benefit | -4,604 | 19 | 3 | 0 |
| Net loss | -117,504 | -108,122 | -162,253 | -171,897 |
| Basic EPS | -0.22 | -0.207 | -0.36 | -0.41 |
| Diluted EPS | -0.22 | -0.207 | -0.36 | -0.41 |
| Basic Average Shares | 529,303,984 | 522,663,271 | 446,988,046 | 417,361,147 |
| Diluted Average Shares | 529,303,984 | 522,663,271 | 446,988,046 | 417,361,147 |
RECURSION PHARMACEUTICALS, INC. (RXRX)
RECURSION PHARMACEUTICALS, INC. (RXRX)